Investor Noubar Afeyan warns against a backlash to science in the U.S.
statnews.com••business
Key Points:
- Noubar Afeyan, a leading biotech investor, warned in his annual letter that anti-science sentiment in the U.S. threatens to reduce life expectancy and hinder biotech innovation.
- Afeyan cautioned that this backlash could also enable China to gain a scientific and economic advantage over the U.S.
- The letter was released by Afeyan’s Flagship Pioneering on the opening day of the J.P. Morgan Healthcare Conference, reinforcing concerns he expressed at last year’s STAT Summit.
